(Q33826480)

29 July 2017

1 reference

title

Substance P antagonists: the next breakthrough in treating depression? (English)

1 reference

29 July 2017

Baby S

1

1 reference

29 July 2017

Nguyen M

series ordinal

2

1 reference

29 July 2017

Tran D

series ordinal

3

1 reference

29 July 2017

Raffa RB

series ordinal

4

1 reference

29 July 2017

publication date

1 December 1999

1 reference

Journal of Clinical Pharmacy and Therapeutics

29 July 2017

published in

1 reference

29 July 2017

volume

24

1 reference

29 July 2017

issue

6

1 reference

29 July 2017

page(s)

461-469

1 reference

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Epidemiology of affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Drug treatment of depression in the 1990s. An overview of achievements and future possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

New antidepressant drugs and the treatment of depression in the medically ill patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Possible role(s) of neurokinins in CNS development and neurodegenerative or other disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Tachykinin receptors: a radioligand binding perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Regional distribution of substance P, neurokinin alpha and neurokinin beta in rat spinal cord, nerve roots and dorsal root ganglia, and the effects of dorsal root section or spinal transection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Distribution of cells containing mRNAs encoding substance P and neurokinin B in the rat central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Isolation and characterisation of the human lung NK-1 receptor cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Molecular cloning, structural characterization and functional expression of the human substance P receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Molecular characterisation, expression and localisation of human neurokinin‐3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

cDNA sequence and heterologous expression of the human neurokinin-3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

The primary structure and gene organization of human substance P and neuromedin K receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Nonpeptide antagonists herald new era in tachykinin research

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1- azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonisst

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Activity and Distribution of Binding Sites in Brain of a Nonpeptide Substance P (NK 1 ) Receptor Antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Role of muscarinic receptor subtypes in central antinociception

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

A potent and selective non-peptide antagonist of the neurokinin a (NK2) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Perturbation of Rat Brain Serotonergic Systems Results in an Inverse Relation Between Substance P and Serotonin Concentrations Measured in Discrete Nuclei

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Serotonin and substance P coexist in neurons of the rat's central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Immunohistochemical evidence of substance P-like immunoreactivity in some 5-hydroxytryptamine-containing neurons in the rat central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Monoaminergic modulation of the sensitivity of neurones in the cingulate cortex to iontophoretically applied substance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Increased levels of substance P and cholecystokinin in rat cerebral cortex following repeated electroconvulsive shock and subchronic treatment with a serotonin uptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

CSF substance P immunoreactivity in affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behavior in the cat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

Reward for persistence in substance P research

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

PSYCHOPHARMACOLOGY:Can the Placebo Be the Cure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00257.X

10.1046/J.1365-2710.1999.00257.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference